Quantcast

Latest CytRx Stories

2015-01-22 08:29:53

Aldoxorubicin Demonstrates 2-Fold Increase in Likelihood of Surviving More than 2 Years versus Doxorubicin and 27% Reduction in the Risk of Death LOS ANGELES, Jan.

2015-01-20 08:31:24

Company does not expect estimated timelines to materially change LOS ANGELES, Jan.

2015-01-08 08:30:17

Aldoxorubicin Showed 66% Complete or Partial Responses and No Tumor Progression in KS Patients with Excellent Tolerability LOS ANGELES, Jan.

2015-01-06 08:29:31

Aldoxorubicin Shows a Complete Response, Tumor Shrinkage, Prolonged Stable Disease, and Favorable Tolerability in Patients LOS ANGELES, Jan.

2014-12-03 08:30:41

Company Continues to Expect Clinical Trial Timelines to Remain Materially Unchanged and Expeditiously Resolved LOS ANGELES, Dec.

2014-11-18 08:30:20

All Currently Enrolled Patients Can Continue Receiving Aldoxorubicin Therapy or Comparator Drugs; One Inclusion/Exclusion Criteria to be Amended for New Trial Patients to Add Additional Safety Measure

2014-11-04 08:33:26

LOS ANGELES, Nov.


Word of the Day
upstander
  • A person who stands up for something, as contrasted to a bystander who remains inactive.
  • One of the upright handlebars on a traditional Inuit sled.
The word 'upstander' in the first sense here is a play on the word 'bystander' and the idea of 'standing up' for something.